{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:37:24Z","timestamp":1790649444496,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T00:00:00Z","timestamp":1644364800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.ebiom.2022.103894","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T06:51:28Z","timestamp":1645512688000},"page":"103894","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Protease-anti-protease compartmentalization in SARS-CoV-2 ARDS: Therapeutic implications"],"prefix":"10.1016","volume":"77","author":[{"given":"Oisin F.","family":"McElvaney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3122-6937","authenticated-orcid":false,"given":"Takanori","family":"Asakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne L.","family":"Meinig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose L.","family":"Torres-Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1504-0086","authenticated-orcid":false,"given":"Robert S.","family":"Hagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudie","family":"Gabillard-Lefort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5624-1338","authenticated-orcid":false,"given":"Mark P.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leigh B.","family":"Thorne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Borczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emer P.","family":"Reeves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross E.","family":"Zumwalt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Mikami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas P.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9341-2730","authenticated-orcid":false,"given":"Kenichi","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver J.","family":"McElvaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie L.","family":"McEvoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick W.","family":"Mallon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2896-5210","authenticated-orcid":false,"given":"Cormac","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ger","family":"Curley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4534-6470","authenticated-orcid":false,"given":"Matthew C.","family":"Wolfgang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard C.","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel G.","family":"McElvaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ebiom.2022.103894_bib0001","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1001\/jamainternmed.2020.0994","article-title":"Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China","volume":"180","author":"Wu","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ebiom.2022.103894_bib0002","unstructured":"Johns Hopkins coronavirus resource center 13.10.21 2022"},{"issue":"15","key":"10.1016\/j.ebiom.2022.103894_bib0003","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1056\/NEJMra1910234","article-title":"Alpha1-antitrypsin deficiency","volume":"382","author":"Strnad","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ebiom.2022.103894_bib0004","doi-asserted-by":"crossref","first-page":"55","DOI":"10.20411\/pai.v6i1.408","article-title":"Alpha 1 antitrypsin is an inhibitor of the SARS-CoV-2-priming protease TMPRSS2","volume":"6","author":"Azouz","year":"2021","journal-title":"Pathog Immun"},{"issue":"9","key":"10.1016\/j.ebiom.2022.103894_bib0005","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.4049\/jimmunol.178.9.5871","article-title":"Neutrophil elastase up-regulates cathepsin B and matrix metalloprotease-2 expression","volume":"178","author":"Geraghty","year":"2007","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.ebiom.2022.103894_bib0006","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1164\/rccm.202005-1583OC","article-title":"Characterization of the Inflammatory Response to Severe COVID-19 Illness","volume":"202","author":"McElvaney","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ebiom.2022.103894_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.103026","article-title":"A linear prognostic score based on the ratio of interleukin-6 to interleukin-10 predicts outcomes in COVID-19","volume":"61","author":"McElvaney","year":"2020","journal-title":"EbioMedicine"},{"key":"10.1016\/j.ebiom.2022.103894_bib0008","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.12688\/f1000research.26058.1","article-title":"Interleukin-6 signalling in health and disease","volume":"9","author":"Rose-John","year":"2020","journal-title":"F1000Research"},{"issue":"10","key":"10.1016\/j.ebiom.2022.103894_bib0009","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1164\/rccm.201709-1954LE","article-title":"Glycosylation repurposes alpha-1 antitrypsin for resolution of community-acquired pneumonia","volume":"197","author":"McCarthy","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.ebiom.2022.103894_bib0010","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S2213-2600(17)30171-6","article-title":"Keratinocyte growth factor for the treatment of the acute respiratory distress syndrome (KARE): a randomised, double-blind, placebo-controlled phase 2 trial","volume":"5","author":"McAuley","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ebiom.2022.103894_bib0011","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1378\/chest.107.4.1062","article-title":"Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS: plasma IL-1\u03b2 and IL-6 levels are consistent and efficient predictors of outcome over time","volume":"107","author":"Meduri","year":"1995","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.ebiom.2022.103894_bib0012","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nprot.2008.63","article-title":"Measuring elastase, proteinase 3 and cathepsin G activities at the surface of human neutrophils with fluorescence resonance energy transfer substrates","volume":"3","author":"Korkmaz","year":"2008","journal-title":"Nat Protoc"},{"issue":"2","key":"10.1016\/j.ebiom.2022.103894_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.05.042","article-title":"SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract","volume":"182","author":"Hou","year":"2020","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.ebiom.2022.103894_bib0014","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1515\/CCLM.2008.036","article-title":"Evaluation of a new Sebia isoelectrofocusing kit for alpha 1-antitrypsin phenotyping with the Hydrasys System","volume":"46","author":"Zerimech","year":"2008","journal-title":"Clin Chem Lab Med"},{"issue":"8","key":"10.1016\/j.ebiom.2022.103894_bib0015","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.4049\/jimmunol.1801045","article-title":"Circulating truncated alpha-1 antitrypsin glycoprotein in patient plasma retains anti-inflammatory capacity","volume":"202","author":"Reeves","year":"2019","journal-title":"J Immunol"},{"issue":"9","key":"10.1016\/j.ebiom.2022.103894_bib0016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009804","article-title":"Identification of immune correlates of fatal outcomes in critically ill COVID-19 patients","volume":"17","author":"Youngs","year":"2021","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.ebiom.2022.103894_bib0017","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41586-020-2588-y","article-title":"Longitudinal analyses reveal immunological misfiring in severe COVID-19","volume":"584","author":"Lucas","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2022.103894_bib0018","article-title":"Underlying conditions and risk of hospitalisation, ICU admission and mortality among those with COVID-19 in Ireland: a national surveillance study","volume":"5","author":"Bennett","year":"2021","journal-title":"Lancet Reg. Health Eur"},{"issue":"7","key":"10.1016\/j.ebiom.2022.103894_bib0019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0254707","article-title":"Retrospective analysis of demographic factors in COVID-19 patients entering the Mount Sinai health system","volume":"16","author":"Eskandari","year":"2021","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ebiom.2022.103894_bib0020","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2030340","article-title":"Tocilizumab in patients hospitalized with Covid-19 pneumonia","volume":"384","author":"Salama","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ebiom.2022.103894_bib0021","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1465-9921-7-61","article-title":"WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung","volume":"7","author":"Bingle","year":"2006","journal-title":"Respir Res"},{"issue":"1","key":"10.1016\/j.ebiom.2022.103894_bib0022","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1186\/s13063-020-04680-w","article-title":"The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: a structured summary of a study protocol for a randomised controlled trial","volume":"21","author":"Cotter","year":"2020","journal-title":"Trials"},{"issue":"5","key":"10.1016\/j.ebiom.2022.103894_bib0023","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1086\/377238","article-title":"Local impairment of anti-neutrophil elastase capacity in community-acquired pneumonia","volume":"188","author":"Greene","year":"2003","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.ebiom.2022.103894_bib0024","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1517\/14728222.12.2.145","article-title":"Targeting neutrophil elastase in cystic fibrosis","volume":"12","author":"Kelly","year":"2008","journal-title":"Expert Opin Ther Targets"},{"issue":"12","key":"10.1016\/j.ebiom.2022.103894_bib0025","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/j.1365-2443.2005.00905.x","article-title":"Nrf2-deficient mice are highly susceptible to cigarette smoke-induced emphysema","volume":"10","author":"Iizuka","year":"2005","journal-title":"Genes Cells"},{"issue":"1","key":"10.1016\/j.ebiom.2022.103894_bib0026","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1038\/s41467-020-18764-3","article-title":"SARS-CoV2-mediated suppression of NRF2-signalling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate","volume":"11","author":"Olagnier","year":"2020","journal-title":"Nat Commun"},{"issue":"19","key":"10.1016\/j.ebiom.2022.103894_bib0027","doi-asserted-by":"crossref","first-page":"9337","DOI":"10.1128\/JVI.00603-08","article-title":"Herpes simplex virus downregulates secretory leukocyte protease inhibitor: a novel immune evasion mechanism","volume":"82","author":"Fakioglu","year":"2008","journal-title":"J Virol"},{"issue":"6","key":"10.1016\/j.ebiom.2022.103894_bib0028","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1183\/09031936.02.00253202","article-title":"Role of secretory leukocyte protease inhibitor in the development of subclinical emphysema","volume":"19","author":"Betsuyaku","year":"2002","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.ebiom.2022.103894_bib0029","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1164\/rccm.202104-0833LE","article-title":"Therapeutic application of alpha-1 antitrypsin in COVID-19","volume":"204","author":"Ritzmann","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ebiom.2022.103894_bib0030","article-title":"Tocilizumab in the management of COVID-19: a preliminary report","author":"Li","year":"2020","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.ebiom.2022.103894_bib0031","article-title":"Interleukin-6 receptor antagonists in critically ill patients with covid-19","author":"Gordon","year":"2021","journal-title":"N Engl J Med"},{"issue":"8738","key":"10.1016\/j.ebiom.2022.103894_bib0032","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/0140-6736(91)91167-S","article-title":"Aerosol alpha 1-antitrypsin treatment for cystic fibrosis","volume":"337","author":"McElvaney","year":"1991","journal-title":"Lancet"},{"issue":"Suppl 4","key":"10.1016\/j.ebiom.2022.103894_bib0033","doi-asserted-by":"crossref","first-page":"S346","DOI":"10.1513\/AnnalsATS.201507-469KV","article-title":"Delivery of alpha-1 antitrypsin to airways","volume":"13","author":"Griese","year":"2016","journal-title":"Ann Am Thorac Soc"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396422000780?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396422000780?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:14:33Z","timestamp":1762456473000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396422000780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":33,"alternative-id":["S2352396422000780"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2022.103894","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Protease-anti-protease compartmentalization in SARS-CoV-2 ARDS: Therapeutic implications","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2022.103894","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103894"}}